The present invention provides an improved and commercially viable process for preparation of erlotinib substantially free of N-methoxyethyl impurity, namely N-[(3-ethynylphenyl)-(2-methoxyethyl)]-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, and its pharmaceutically acceptable acid addition salts thereof in High purity and in high yield. According to the present invention, erlotinib or a pharmaceutically acceptable acid addition salt of erlotinib substantially free of N-methoxyethyl impurity is prepared by isolating erlotinib or a pharmaceutically acceptable salt of erlotinib from a solvent medium comprising dimethyl sulfoxide and an alcoholic solvent.
本发明提供了一种改进的、商业上可行的制备
厄洛替尼的方法,该方法可以使
厄洛替尼及其药用酸盐在高纯度和高收率下几乎不含N-甲氧基乙基杂质,即N-[(3-
乙炔基苯基)-(2-甲氧基乙基)]-6,7-
双(2-甲氧基乙氧基)-4-
喹唑啉胺。根据本发明,通过从包含
二甲基亚砜和醇溶剂的溶剂介质中分离
厄洛替尼或其药用酸盐,可以制备几乎不含N-甲氧基乙基杂质的
厄洛替尼或其药用酸盐。